A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201

This study has been terminated.
(The biological effect seen with natalizumab was not sufficient to warrant further development in RA.)
Sponsor:
Collaborator:
Biogen Idec
Information provided by:
Elan Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00831649
First received: January 27, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)